| [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment (NCT01633255) | National Cancer Institute (NCI) | 2012-04-18 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (NCT01567709) | National Cancer Institute (NCI) | 2012-04-16 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers (NCT01585428) | National Cancer Institute (NCI) | 2012-04-13 |
| Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01540565) | National Cancer Institute (NCI) | 2012-04-09 |
| Vemurafenib and White Blood Cell Therapy for Advanced Melanoma (NCT01585415) | National Cancer Institute (NCI) | 2012-04-09 |
| Continuous Infusion of rhIL-15 for Adults With Advanced Cancer (NCT01572493) | National Cancer Institute (NCI) | 2012-04-04 |
| Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01533194) | National Cancer Institute (NCI) | 2012-04-01 |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01576172) | National Cancer Institute (NCI) | 2012-03-30 |
| Clobetasol for Oral Graft-Versus-Host Disease (NCT01557517) | National Cancer Institute (NCI) | 2012-03-28 |
| Imaging Studies and the Development of Multiple Myeloma (NCT01571726) | National Cancer Institute (NCI) | 2012-03-27 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (NCT01552356) | National Cancer Institute (NCI) | 2012-03-19 |
| FdCyd and THU for Advanced Solid Tumors (NCT01534598) | National Cancer Institute (NCI) | 2012-03-05 |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976) | National Cancer Institute (NCI) | 2012-03-01 |
| Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (NCT01560260) | National Cancer Institute (NCI) | 2012-03-01 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522) | National Cancer Institute (NCI) | 2012-03-01 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma (NCT01568632) | National Cancer Institute (NCI) | 2012-03-01 |
| Diet and Nutrition Pilot Study for Chinese Adolescents and Their Mothers (NCT01517139) | National Cancer Institute (NCI) | 2012-03-01 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (NCT02883049) | National Cancer Institute (NCI) | 2012-02-29 |
| Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer (NCT01507428) | National Cancer Institute (NCI) | 2012-02-22 |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma (NCT01547806) | National Cancer Institute (NCI) | 2012-02-22 |
| Cancer Symptom Data From Multiple Treatment Centers (NCT01547845) | National Cancer Institute (NCI) | 2012-02-10 |
| Studying Blood Toxicity in Workers Exposed to Formaldehyde (NCT01547858) | National Cancer Institute (NCI) | 2012-02-09 |
| AMG 386 and Abiraterone for Advanced Prostate Cancer (NCT01553188) | National Cancer Institute (NCI) | 2012-02-08 |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas (NCT01514201) | National Cancer Institute (NCI) | 2012-02-01 |
| Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (NCT01538095) | National Cancer Institute (NCI) | 2012-02-01 |
| Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer (NCT01533181) | National Cancer Institute (NCI) | 2012-02-01 |
| Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer (NCT01533246) | National Cancer Institute (NCI) | 2012-02-01 |
| Pazopanib and ARQ 197 for Advanced Solid Tumors (NCT01468922) | National Cancer Institute (NCI) | 2012-01-23 |
| Clinical and Genetic Studies of Li-Fraumeni Syndrome (NCT01443468) | National Cancer Institute (NCI) | 2012-01-17 |
| Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia (NCT01578109) | National Cancer Institute (NCI) | 2012-01-13 |
| Tivantinib in Treating Patients With Metastatic Prostate Cancer (NCT01519414) | National Cancer Institute (NCI) | 2012-01-11 |
| Pomalidomide for Kaposi Sarcoma in People With or Without HIV (NCT01495598) | National Cancer Institute (NCI) | 2012-01-10 |
| Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (NCT01434303) | National Cancer Institute (NCI) | 2012-01-10 |
| Initial Study of Gallbladder Cancer in Chile (NCT01520259) | National Cancer Institute (NCI) | 2012-01-10 |
| Cancer Vaccine Targeting Brachyury Protein in Tumors (NCT01519817) | National Cancer Institute (NCI) | 2012-01-05 |
| Testing a Spanish Version of a Patient Toxicity Questionnaire (NCT01517152) | National Cancer Institute (NCI) | 2012-01-04 |
| HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda (NCT01520272) | National Cancer Institute (NCI) | 2012-01-02 |
| Internet-Based and Self-Reports in Assessing Diet and Physical Activity Within AARP (NCT03268577) | National Cancer Institute (NCI) | 2012-01-01 |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma (NCT01462695) | National Cancer Institute (NCI) | 2012-01-01 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01515176) | National Cancer Institute (NCI) | 2012-01-01 |
| Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (NCT01502410) | National Cancer Institute (NCI) | 2012-01-01 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (NCT01519427) | National Cancer Institute (NCI) | 2012-01-01 |
| NHS-IL12 for Solid Tumors (NCT01417546) | National Cancer Institute (NCI) | 2011-12-12 |
| Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT01468909) | National Cancer Institute (NCI) | 2011-12-12 |
| Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer (NCT01325311) | National Cancer Institute (NCI) | 2011-12-01 |
| Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (NCT01495572) | National Cancer Institute (NCI) | 2011-12-01 |
| Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT01481129) | National Cancer Institute (NCI) | 2011-12-01 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (NCT01480154) | National Cancer Institute (NCI) | 2011-11-23 |
| Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia (NCT01420926) | National Cancer Institute (NCI) | 2011-11-16 |
| Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316) | National Cancer Institute (NCI) | 2011-11-11 |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01351896) | National Cancer Institute (NCI) | 2011-11-02 |
| Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma (NCT01447914) | National Cancer Institute (NCI) | 2011-11-01 |
| Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery (NCT01433913) | National Cancer Institute (NCI) | 2011-11-01 |
| Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants (NCT01497431) | National Cancer Institute (NCI) | 2011-11-01 |
| Imaging Study for FdCyd and THU Cancer Treatment (NCT01479348) | National Cancer Institute (NCI) | 2011-11-01 |
| Providing Access to Cord Blood Units for Transplants (NCT01479582) | National Cancer Institute (NCI) | 2011-10-27 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (NCT01468896) | National Cancer Institute (NCI) | 2011-10-26 |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01459380) | National Cancer Institute (NCI) | 2011-10-11 |
| Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma (NCT01468311) | National Cancer Institute (NCI) | 2011-10-11 |
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer (NCT01457131) | National Cancer Institute (NCI) | 2011-10-06 |
| AZD7451 for Recurrent Gliomas (NCT01468324) | National Cancer Institute (NCI) | 2011-10-05 |
| Collection of Tissue Blocks or Slides From Patients With Cancer (NCT02810405) | National Cancer Institute (NCI) | 2011-10-03 |
| Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers (NCT01336387) | National Cancer Institute (NCI) | 2011-10-01 |
| Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma (NCT01466881) | National Cancer Institute (NCI) | 2011-10-01 |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors (NCT01352962) | National Cancer Institute (NCI) | 2011-09-26 |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (NCT01362803) | National Cancer Institute (NCI) | 2011-09-21 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia (NCT01627041) | National Cancer Institute (NCI) | 2011-09-16 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease (NCT01441063) | National Cancer Institute (NCI) | 2011-09-13 |
| Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) (NCT01419561) | National Cancer Institute (NCI) | 2011-09-08 |
| ECI301 and Radiation for Advanced or Metastatic Cancer (NCT01441115) | National Cancer Institute (NCI) | 2011-09-06 |
| Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (NCT01403415) | National Cancer Institute (NCI) | 2011-09-01 |
| -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer (NCT01441128) | National Cancer Institute (NCI) | 2011-09-01 |
| Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment (NCT01421862) | National Cancer Institute (NCI) | 2011-09-01 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT01468818) | National Cancer Institute (NCI) | 2011-09-01 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate (NCT01426334) | National Cancer Institute (NCI) | 2011-09-01 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01369849) | National Cancer Institute (NCI) | 2011-09-01 |
| Breath Test for Chemicals (Volatile Organic Compounds) (NCT01437033) | National Cancer Institute (NCI) | 2011-08-29 |
| TKM 080301 for Primary or Secondary Liver Cancer (NCT01437007) | National Cancer Institute (NCI) | 2011-08-26 |
| Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (NCT01349959) | National Cancer Institute (NCI) | 2011-08-15 |
| MR Image Guided Therapy in Prostate Cancer (NCT01377753) | National Cancer Institute (NCI) | 2011-08-12 |
| Intestine Bacteria and Breast Cancer Risk (NCT01461070) | National Cancer Institute (NCI) | 2011-08-10 |
| Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (NCT01383343) | National Cancer Institute (NCI) | 2011-08-01 |
| Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye (NCT01413191) | National Cancer Institute (NCI) | 2011-08-01 |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems (NCT01419548) | National Cancer Institute (NCI) | 2011-07-29 |
| Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients (NCT01402284) | National Cancer Institute (NCI) | 2011-07-21 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692) | National Cancer Institute (NCI) | 2011-07-20 |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (NCT01391962) | National Cancer Institute (NCI) | 2011-07-18 |
| MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (NCT01415765) | National Cancer Institute (NCI) | 2011-07-15 |
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma (NCT01266031) | National Cancer Institute (NCI) | 2011-07-12 |
| Amatuximab for High Mesothelin Cancers (NCT01413451) | National Cancer Institute (NCI) | 2011-07-12 |
| BRCA Mutations in Latinas (NCT01251900) | National Cancer Institute (NCI) | 2011-07-07 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01371981) | National Cancer Institute (NCI) | 2011-07-06 |
| Study of Lymphoma in Asia (NCT01584141) | National Cancer Institute (NCI) | 2011-07-05 |
| The Ultrasound Study of Tamoxifen (NCT01582074) | National Cancer Institute (NCI) | 2011-07-05 |
| RO4929097 in Treating Patients With Recurrent Invasive Gliomas (NCT01269411) | National Cancer Institute (NCI) | 2011-07-01 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01375829) | National Cancer Institute (NCI) | 2011-06-27 |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib (NCT01375569) | National Cancer Institute (NCI) | 2011-06-22 |